According to a recent LinkedIn post from Actithera, the company plans to attend ESRR 2026 in Bergen, Norway, a specialized meeting focused on radiopharmacy and radiochemistry. The post notes that representatives Dimitrios Mantzilas and Elisa Fiorito, Ph.D. are expected to engage with peers, discuss ongoing work, and pursue potential collaborations in radioligand therapy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that Actithera is prioritizing deeper integration within the radiopharmaceutical and oncology innovation community, which could support future partnering or co-development opportunities. For investors, active participation in a niche scientific forum may indicate efforts to advance the company’s pipeline visibility, strengthen its network with academic and industry stakeholders, and potentially position itself for future strategic or funding discussions.